U.S. markets closed
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • Dow 30

    35,144.31
    +82.76 (+0.24%)
     
  • Nasdaq

    14,840.71
    +3.72 (+0.03%)
     
  • Russell 2000

    2,216.92
    +7.27 (+0.33%)
     
  • Crude Oil

    72.17
    +0.10 (+0.14%)
     
  • Gold

    1,797.40
    -4.40 (-0.24%)
     
  • Silver

    25.25
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1811
    +0.0040 (+0.34%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3814
    +0.0060 (+0.44%)
     
  • USD/JPY

    110.3770
    -0.1330 (-0.12%)
     
  • BTC-USD

    37,603.80
    +3,163.32 (+9.18%)
     
  • CMC Crypto 200

    905.01
    -10.48 (-1.14%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Biogen now says it plans to complete 'confirmatory' study for Alzheimer's drug earlier than required

·1 min read
Biogen now says it plans to complete 'confirmatory' study for Alzheimer's drug earlier than required

Shares of Biogen Inc. were up 0.8% in premarket trading on Wednesday after the company and Eisai Inc. said they plan to speed up the completion of what is called a "confirmatory" clinical trial for its recently approved Alzheimer's disease treatment. In the weeks since the drug's approval in the U.S., Aduhelm has faced criticism over how it was priced and whether or not the clinical data were strong enough to support the approval. In the new statement, the companies said they they now plan to co